Posts Tagged ‘department of medicine’

University Hospitals Case Medical Center Remains Among the Elite in U.S. News & World Report Annual Survey

July 16, 2010

University Hospitals Case Medical Center (UHCMC) has again ranked among the elite in the latest U.S. News & World Report hospital rankings.  In this year’s survey, UHCMC ranked seven clinical specialties in the top 50 for hospitals and health systems nationwide.

Top among clinical departments at UHCMC, the Department of Medicine again contributed four of the specialties – Gastroenterology (28), Geriatrics (28), Cancer (34), and Pulmonology (42). This contribution by the Department of Medicine figured significantly into UHCMC joining only 152 other hospitals, or the top 3% of the nation’s 5,000 eligible healthcare organizations.

“This consistent level of excellence in compassionate, cost-effective patient care is a testament to the quality and dedication of the full time faculty in the Department of Medicine and to the leadership of our organizations.”

Richard A. Walsh, MD, Chairman, Department of Medicine

Angiotensin-Receptor Blockades (ARBs) Found to Raise Risk of Cancer

July 9, 2010

Dr. Daniel Simon M.D., Division Chief of Cardiovascular Medicine and Director of HM-Heart and Vascular Institute at UHCMC; Dr. James Fang M.D., Section Chief of Heart Failure and Medical Director of Heart Transplantation at UHCMC; IIke Sipahi M.D., Associate Director of Heart Failure & Transplantation at UHCMC at the Harrington-McLaughlin Heart & Vascular Institute of UHCMC researched the effects of Angiotensin-Receptor Blockers (ARBs) on the risk of cancer.

ARBs are a widely utilized drug class used for treatment of hypertension, heart failure, diabetic nephropathy, and recently, for cardiovascular risk reduction.

Randomized controlled trials of ARBs with a follow-up of at least 1 year, and enrolling at least 100 patients were included in this meta-analysis. Information on new cancer development (first diagnosis) was available for 61,590 patients from five trials. Cancer data on common types of solid organ cancers such as lung and prostate cancer were available for 68,402 patients from five trials, and data on cancer deaths were available for 93,515 patients from eight trials.

The meta-analysis showed that patients randomly assigned to receive ARBs had a significantly increased risk of new cancer occurrence compared with patients in control groups (7.2%vs 6.0%). Specifically, the risk of lung cancer was increased by 25%, which was also statistically significant.

“We have found the risk of new cancers was increased with these medications by 8-11 percent.  Most importantly, risk of lung cancer was increased by 25 percent,” said Dr. Sipahi. Although there was no statistically significant excess in cancer deaths (1.8% with ARBs vs 1.6% with control) the investigators pointed out that the average duration of follow-up of 4 years may be too short to capture cancer deaths.

“In medicine, physicians must balance the benefits and risks of all drug and device therapies.  We recommend that patients discuss the findings of this study with their physicians since ARBs are effective agents in the treatment of high blood pressure and heart failure,” said Dr. Simon.

They conclude that because of the limited data, it is not possible to draw conclusions about the exact risk of cancer associated with each individual ARB on the market, but they stated that their findings need further investigation.

In response to this publication from Case Western Reserve University, the European Medicines Agency (EMA) of the European Union announced that they started an investigation about the possible cancer risk of ARBs.

“This is the first time an association between ARBs and cancer development is suggested,” Dr. Sipahi continued. “While our findings are robust, they need to be replicated in other studies before they can be considered as definitive.”

The US Food and Drug Administration has not made any statement regarding this issue yet.

Correlation Between Methicillin-Resistant Staphylococcus Aureus and Cystic Fibrosis Proven

July 9, 2010

Led by Dr. Elliott Dasenbrook MD MHS, Associate Director of The Adult Cystic Fibrosis Program, a UHCMC team in the Division of Pulmonary, Critical Care, and Sleep Medicine have published the findings from a major study about cystic fibrosis (CF) survival rates in the June 16 issue of JAMA.

Specifically, the study observed patients with CF who had methicillin-resistant Staphylococcus aureus (MRSA) detected in their respiratory tract.

The team composed a study with 19,833 CF patients across the nation between ages 6 and 45.  Times until death after diagnosis with MRSA were recorded in order to compare survival between CF patients with and without respiratory tract MRSA.

The unadjusted mortality rate was 18.3 deaths (95% confidence interval [CI], 17.5-19.1) per 1000 patient-years in patients without MRSA and 27.7 deaths (95% CI, 25.3-30.4) per 1000 patient-years in those with MRSA.  The team showed that there is a significantly higher rate of death in CF in people that have MRSA.

“Our study findings may prompt many doctors to reconsider how they care for CF patients,” says Dr. Dasenbrook. He adds, “Until now, some CF doctors weren’t aggressively treating patients with MRSA.  Doctors often viewed MRSA to not be as important as other respiratory-tract infections. With our study findings, treatment patterns may changes as the risk of death is 1.3 times greater for CF patients with MRSA.”

hematology oncology publications :: Q2 | 2010

July 8, 2010

Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia
Harr M, Caimi P, McColl K, Zhong F, Patel S, Barr P, Distelhorst C.
Cell Death Differ. 2010 Mar

Non-Hodgkin’s lymphoma in the elderly
Caimi PF, Barr PM, Berger NA, Lazarus HM.
Drugs Aging. 2010 Mar

Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL
Kaplan D, Meyerson HJ, Li X, Drasny C, Liu F, Costaldi M, Barr P, Lazarus HM.
Cytometry B Clin Cytom. 2010 Mar

Toxicity of sunitinib plus bevacizumab in renal cell carcinoma
Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Ivy P, Chen HX, Dowlati A, Dreicer R.
J Clin Oncol. 2010 Jun

Variability of pulse oximetry measurement over 1 year in children with sickle cell disease depends on initial oxygen saturation measurement
Mullin JE, Cooper B, Seicean S, Strunk R, Rosen C, Redline S, Kemp J, DeBaun MR.
Pediatr Blood Cancer. 2010 Jul

Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia
Harr MW, Caimi P, McColl K, Zhong F, Patel S, Barr P, Distelhorst C.
Cell Death Differ. 2010 Mar

O-fucose modulates notch-controlled blood lineage commitment
Yan Q, Yao D, Wei LL, Huang Y, Myers J, Zhang L, Xin W, Shim J, Man Y, Petryniak B, Gerson S, Lowe JB, Zhou L.
Am J Pathol. 2010 Jun

Umbilical cord blood-selected CD133(+) cells exhibit vasculogenic functionality in vitro and in vivo
Finney MR, Fanning LR, Joseph ME, Goldberg JL, Greco NJ, Bhakta S, Winter DG, Forster M, Scheid PE, Sabe M, Pompili VJ, Laughlin MJ.
Cytotherapy. 2010

Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL
Kaplan D, Meyerson HJ, Li X, Drasny C, Liu F, Costaldi M, Barr P, Lazarus HM.
Cytometry B Clin Cytom. 2010 Mar

Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis
Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, Qin H, Liu L, Qian W, Ransohoff RM, Bergmann C, Stohlman S, Tuohy VK, Li X.
Immunity. 2010 Mar

CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis
Liu L, Belkadi A, Darnall L, Hu T, Drescher C, Cotleur AC, Padovani-Claudio D, He T, Choi K, Lane TE, Miller RH, Ransohoff RM.
Nat Neurosci. 2010 Mar

ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors
Bagai R, Fan W, Ma PC.
IDrugs. 2010 Jun

A segregation analysis of Barrett’s esophagus and associated adenocarcinomas
Sun X, Elston R, Barnholtz-Sloan J, Falk G, Grady WM, Kinnard M, Mittal SK, Willis JE, Markowitz S, Brock W, Chak A.
Cancer Epidemiol Biomarkers Prev. 2010 Mar

Confirmation of Linkage to and Localization of Familial Colon Cancer Risk Haplotype on Chromosome 9q22
Gray-McGuire C, Guda K, Adrianto I, Lin CP, Natale L, Potter JD, Newcomb P, Poole EM, Ulrich CM, Lindor N, Goode EL, Fridley BL, Jenkins R, Le Marchand L, Casey G, Haile R, Hopper J, Jenkins M, Young J, Buchanan D, Gallinger S, Adams M, Lewis S, Willis J, Elston R, Markowitz SD, Wiesner GL.
Cancer Res. 2010 Jul

Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70
Ferenczi K, Ohtola J, Aubert P, Kessler M, Sugiyama H, Somani AK, Gilliam AC, Chen JZ, Yeh I, Matsuyama S, McCormick TS, Cooper KD.
Br J Dermatol. 2010 Apr

Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells
Rana S, Gupta K, Gomez J, Matsuyama S, Chakrabarti A, Agarwal ML, Agarwal A, Agarwal MK, Wald DN.
FASEB J. 2010 Jun

Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis
LaRusch GA, Mahdi F, Shariat-Madar Z, Adams G, Sitrin RG, Zhang WM, McCrae KR, Schmaier AH.
Blood. 2010 Jun

Comorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancer
Koroukian SM, Xu F, Bakaki PM, Diaz-Insua M, Towe TP, Owusu C.
J Gerontol A Biol Sci Med Sci. 2010 Mar

Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis
Stavrou E, Schmaier AH.
Thromb Res. 2010 Mar

Much-needed complement to cholesterol testing

June 25, 2010

For patients outside the highest and lowest traditional risk factor categories, based on factors like high cholesterol, smoking, diabetes, hypertension and family history of heart disease, MRP-8/14 could become a prominent diagnostic tool. “We are attempting to determine whether the use of MRP-8/14 should sway us toward more aggressive preventive therapies,” says Carl Orringer, MD, the HarringtonMcLaughlin Chair in Preventive Cardiovascular Medicine at the School of Medicine.

Currently, a “high-sensitivity C-reactive protein” (hs-CRP) assay is sometimes used in conjunction with cholesterol tests to assess heart disease risk. Like hs-CRP, MRP-8/14 represents a different biological process than cholesterol and is likely to serve as a complement to, not a substitute for, cholesterol screening. Of cholesterol testing’s shortcomings, Dr. Orringer says, “Relying on cholesterol alone is ignoring the inflammation that lights the fuse that sets off the explosion that is the heart ttack.”

Dr. Orringer, who developed an innovative heart attack risk assessment program that uses CT scans to see whether a person has hardening of the arteries, believes that MRP-8/14 may come to be incorporated to aid in risk estimation.

“A person’s heart attack risk is related to how much calcium is in the arteries—the more calcium, the greater the risk,” Dr. Orringer explains. “Those with calcium in their arteries indicating atherosclerosis might be really good candidates for MRP-8/14 evaluation to see who is at the highest risk.”

Director of Institute for Transformative Molecular Medicine, Inaugural Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation

June 25, 2010

Pamela B. Davis, M.D., Ph.D., dean of the Case Western Reserve University School of Medicine, announced the appointment of Jonathan S. Stamler, M.D., as the director of the Institute for Transformative Molecular Medicine and the first to hold the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at the Case Western Reserve University Cardiovascular Center and University Hospitals Harrington-McLaughlin Heart & Vascular Institute.

The newly established chair was made possible by a $1.5 million gift from the Reitman Family Foundation and was slated to be held by a preeminent physician scientist dedicated to advancing cardiovascular medicine through compassionate patient care, clinical research, and training of fellows and residents.

As director of the Institute for Transformative Molecular Medicine, primarily based in the Department of Medicine, Stamler will be charged with developing the Institute, with purview across Case Western Reserve University and University Hospitals. His efforts will catalyze scientific discoveries in molecular medicine, formulate new therapies that benefit humankind, and inspire the next generation of physician scientists.

His research specifically has led to elucidating the fundamental role of nitric oxide in control of complex physiological responses through S-nitrosylation, a protein modification that he discovered. His work has helped to transform the simple notion of cellular redox state into the concept of a dynamic and precisely regulated mechanism for control of protein function, analogous to phosphorylation, but operating through covalent modifications at cysteine thiols. The ramifications of his work extend to all major classes of proteins and accumulating evidence suggests that protein S-nitrosylation is aberrant in many diseases.

Stamler completed his undergraduate studies at Brandeis University, earned his medical degree from Mount Sinai School of Medicine, and completed his medical residency and fellowship training in both cardiology and pulmonary medicine at Harvard Medical School and the Brigham and Women’s Hospital. He joined the faculty of Harvard Medical School as Assistant Professor of Medicine in October 1993. In December of 1993, Stamler joined the faculty of Duke University, where he is currently the George Barth Geller Professor of Research in Cardiovascular Disease and Professor of Medicine and Biochemistry.

Renowned researcher to lead transformative institute

June 25, 2010

A new initiative in translational research at Case Western Reserve University Department of Medicine and University Hospitals promises to catalyze scientific discoveries, formulate new therapies and inspire the next generation of physician-scientists.

Leading the effort will be one of the school’s newest additions: Jonathan S. Stamler, MD, who will serve as founding director of the Institute for Transformative Molecular Medicine. Dr. Stamler is also the first to hold the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at the Case Cardiovascular Center and University Hospitals Harrington-McLaughlin Heart & Vascular Institute.

“This newly established chair in cardiovascular investigation and its relationship to the Institute for Transformative Molecular Medicine will accelerate our scientific research to its full potential and provide new cures and therapies for the patients we serve,” says Richard A. Walsh, MD, physician-in-chief at University Hospitals and the John H. Hord Professor and chair of the Department of Medicine at Case Western Reserve University.

Prostate Cancer at CWRUmedicine

June 20, 2010

Worldwide, prostate cancer is one of the most common types of cancer found in men. Learning more about prostate cancer and treatment options can help you and your loved ones take an active part in making choices about care.

* Click here to read about new research conducted by the Division of Hematology Oncology at Case Western Reserve University.

The prostate is a chestnut-sized gland below the bladder, which contributes most of the fluid that combines with a man’s sperm to make semen.

Prostate cancer is the most common cancer other than skin cancer in American men and is the second leading cause of cancer death in men.

The American Cancer Society estimates that more than 234,000 men will be diagnosed with prostate cancer in 2006. Incidence rates for the disease are higher for African-American men than for white men.

Other Prostate Cancer Survivors ::

Harry Belafonte
Musician, actor and social activist Harry Belafonte

Robert De Niro
Actor Robert De Niro

Rudy Giuliani
Former New York City Mayor Rudy Giuliani

John Kerry
U.S. Senator & 2004 Presidential candidate John Kerry

Nelson Mandela
Former President of South Africa Nelson Mandela